2 reports of this reaction
4.8% of all ALUMINUM ZIRCONIUM TRICHLOROHYDREX GLY reports
#1 most reported adverse reaction
APPLICATION SITE RASH is the #1 most commonly reported adverse reaction for ALUMINUM ZIRCONIUM TRICHLOROHYDREX GLY, manufactured by Bath and Body Works, Distr.. There are 2 FDA adverse event reports linking ALUMINUM ZIRCONIUM TRICHLOROHYDREX GLY to APPLICATION SITE RASH. This represents approximately 4.8% of all 42 adverse event reports for this drug.
Patients taking ALUMINUM ZIRCONIUM TRICHLOROHYDREX GLY who experience application site rash should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
APPLICATION SITE RASH is moderately reported among ALUMINUM ZIRCONIUM TRICHLOROHYDREX GLY users, representing a notable but not dominant share of adverse events.
In addition to application site rash, the following adverse reactions have been reported for ALUMINUM ZIRCONIUM TRICHLOROHYDREX GLY:
The following drugs have also been linked to application site rash in FDA adverse event reports:
APPLICATION SITE RASH has been reported as an adverse event in 2 FDA reports for ALUMINUM ZIRCONIUM TRICHLOROHYDREX GLY. This does not prove causation, but indicates an association observed in post-market surveillance data.
APPLICATION SITE RASH accounts for approximately 4.8% of all adverse event reports for ALUMINUM ZIRCONIUM TRICHLOROHYDREX GLY, making it one of the most commonly reported side effect.
If you experience application site rash while taking ALUMINUM ZIRCONIUM TRICHLOROHYDREX GLY, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.